We are live on
!
Find out more
Sands Capital Management Portfolio holdings
AUM
$25.5B
1-Year Est. Return
26.46%
This Fund
S&P 500
This Quarter
Est. Return
+8.04%
1 Year Est. Return
+26.46%
3 Year Est. Return
+130.81%
5 Year Est. Return
+100.92%
10 Year Est. Return
+877.17%
AUM
$35.4B
AUM Growth
+$439M
(+1.3%)
Cap. Flow
-$1.77B
Cap. Flow
% of AUM
-5.01%
Top 10 Holdings %
Top 10 Hldgs %
52.34%
Holding
71
New
5
Increased
16
Reduced
44
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$260M |
| 2 |
Edwards Lifesciences
EW
|
+$214M |
| 3 |
ABMD
Abiomed Inc
ABMD
|
+$175M |
| 4 |
Alibaba
BABA
|
+$130M |
| 5 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$122M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$535M |
| 2 |
Starbucks
SBUX
|
+$297M |
| 3 |
Baidu
BIDU
|
+$279M |
| 4 |
Visa
V
|
+$175M |
| 5 |
Netflix
NFLX
|
+$141M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 23.64% |
| 2 | Technology | 23.61% |
| 3 | Healthcare | 21.16% |
| 4 | Communication Services | 16.27% |
| 5 | Financials | 10.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Atlassian
TEAM
$26.5B
| $436M | 1.23% |
4,539,740
-234,500
| -5% | -$18.6M |
|
|
ALXN
27
DELISTED
Alexion Pharmaceuticals
ALXN
| $412M | 1.17% |
2,965,227
-259,112
| -8% | -$32.5M |
|
28
Alphabet (Google) Class C
GOOG
$4.11T
| $404M | 1.14% |
6,762,120
-479,440
| -7% | -$28.7M |
|
|
29
Baidu
BIDU
$35.7B
| $352M | 1% |
1,539,273
-1,189,444
| -44% | -$279M |
|
|
LKFT
30
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
| $337M | 0.95% |
2,999,339
+1,155,853
| +63% | +$122M |
|
|
LOXO
31
DELISTED
Loxo Oncology, Inc
LOXO
| $315M | 0.89% |
1,844,830
-163,407
| -8% | -$27.5M |
|
32
Incyte
INCY
$25.8B
| $313M | 0.88% |
4,525,984
-247,225
| -5% | -$17M |
|
|
33
Sarepta Therapeutics
SRPT
$1.64B
| $307M | 0.87% |
+1,901,564
| New | +$260M |
|
|
34
Starbucks
SBUX
$119B
| $296M | 0.84% |
5,208,773
-5,607,989
| -52% | -$297M |
|
35
Las Vegas Sands
LVS
$31.4B
| $261M | 0.74% |
4,397,218
-248,775
| -5% | -$16.7M |
|
36
Floor & Decor
FND
$6.03B
| $203M | 0.57% |
6,730,273
+1,910,998
| +40% | +$77.9M |
|
|
ABMD
37
DELISTED
Abiomed Inc
ABMD
| $200M | 0.56% |
+443,607
| New | +$175M |
|
|
MDSO
38
DELISTED
Medidata Solutions, Inc.
MDSO
| $157M | 0.45% |
2,146,654
-1,111,655
| -34% | -$88.9M |
|
|
NBIS
39
Nebius Group N.V.
NBIS
$37.6B
| $142M | 0.4% |
4,328,994
+470,150
| +12% | +$15.9M |
|
40
iShares MSCI India ETF
INDA
$6.81B
| $125M | 0.35% |
3,855,516
+70,500
| +2% | +$2.44M |
|
41
TSMC
TSM
$1.94T
| $123M | 0.35% |
2,789,949
+324,585
| +13% | +$13.4M |
|
42
Trip.com Group
TCOM
$29B
| $115M | 0.33% |
3,091,784
+407,000
| +15% | +$16.5M |
|
43
Mercado Libre
MELI
$94.5B
| $90.9M | 0.26% |
267,073
+15,800
| +6% | +$5.35M |
|
44
Grupo Aeroportuario del Sureste
ASR
$8.16B
| $67.2M | 0.19% |
327,452
+28,225
| +9% | +$5.19M |
|
45
MakeMyTrip
MMYT
$5.38B
| $65.6M | 0.19% |
2,389,164
+207,700
| +10% | +$6.63M |
|
46
Sea Limited
SE
$66.4B
| $38.6M | 0.11% |
2,794,440
+240,700
| +9% | +$3.47M |
|
47
HDFC Bank
HDB
$123B
| $36.4M | 0.1% |
1,546,624
+394,500
| +34% | +$10.1M |
|
48
Zoetis
ZTS
$32.7B
| $22M | 0.06% |
239,935
+60,800
| +34% | +$5.39M |
|
|
DOCU
49
DocuSign
DOCU
$11.1B
| $21.4M | 0.06% |
406,923
| – | – |
|
50
HUTCHMED
HCM
$1.96B
| $16.4M | 0.05% |
+508,275
| New | +$15.5M |
|
Similar funds
KK
VAI
UIM
Sands Capital Management's Q3 2018 Portfolio in Review
As of Q3 2018, Sands Capital Management held 71 positions worth $35.4B, up 1.3% from $34.9B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Sands Capital Management withdrew a net $1.77B in Q3 2018, closing 3 positions and reducing 44 holdings. Its most notable exit was Credicorp, an estimated $49.8M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 24% of assets, down from 26% a quarter earlier, followed by Technology and Healthcare.
Against the trend, Sands Capital Management opened a new position in Sarepta Therapeutics worth $307M.
- Sands Capital Management's largest Q3 2018 buy was Sarepta Therapeutics: 1,901,564 shares worth $307M.
- Sands Capital Management added most to Edwards Lifesciences in Q3 2018, an estimated $214M increase.
- Sands Capital Management's biggest Q3 2018 reduction was Amazon, cutting an estimated $535M.
- Sands Capital Management fully exited Credicorp in Q3 2018, selling an estimated $49.8M.
- Sands Capital Management's ten largest holdings make up 52% of its $35.4B portfolio in Q3 2018.
- Sands Capital Management opened 5 new positions and closed 3 in Q3 2018.
- Sands Capital Management's portfolio value rose 1.3% quarter-over-quarter to $35.4B.
Based on Sands Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.